长春高新涨2.00%，成交额2.09亿元，主力资金净流入860.94万元

Core Viewpoint - Changchun High-tech's stock price has shown a mixed performance in recent trading sessions, with a year-to-date increase of 24.07% but a slight decline in the last five and twenty trading days [1] Group 1: Stock Performance - As of October 27, Changchun High-tech's stock price rose by 2.00% to 120.20 CNY per share, with a trading volume of 2.09 billion CNY and a turnover rate of 0.44%, resulting in a total market capitalization of 49.034 billion CNY [1] - Year-to-date, the stock has increased by 24.07%, but it has decreased by 0.76% over the last five trading days and by 4.01% over the last twenty trading days [1] - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 2, where it recorded a net purchase of 275 million CNY [1] Group 2: Company Overview - Changchun High-tech was established on June 10, 1993, and listed on December 18, 1996. Its main business includes research, production, and sales of biopharmaceuticals and traditional Chinese medicine, along with real estate development and property management [2] - The revenue composition of the company is 92.83% from pharmaceuticals, 6.81% from real estate, and 0.36% from services [2] - As of June 30, the number of shareholders was 109,100, a decrease of 12.78% from the previous period, with an average of 3,662 circulating shares per shareholder, an increase of 14.66% [2] Group 3: Financial Performance - For the first half of 2025, Changchun High-tech reported a revenue of 6.603 billion CNY, a year-on-year decrease of 0.54%, and a net profit attributable to shareholders of 983 million CNY, down 42.85% year-on-year [2] - The company has distributed a total of 4.791 billion CNY in dividends since its A-share listing, with 3.259 billion CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the third-largest shareholder, holding 8.4381 million shares, a decrease of 3.4502 million shares from the previous period [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Pharmaceutical ETF, with varying changes in their holdings [3]